Cipla

26th August 2022

(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 500087

(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sir/Madam,

Sub: Update on USFDA inspection at Cipla's manufacturing facility in Goa

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that further to United States Food and Drug Administration (USFDA) inspection at the Company's Goa manufacturing facility in September 2019 and the warning letter received in February 2020, the Goa plant recently underwent a USFDA inspection from 16th – 26th August 2022.

On conclusion of the inspection, the Company has now received 6 observations with some referencing to the observations made during the September 2019 inspection. There are no data integrity (DI) observations. The Company will work closely with the USFDA and is committed to address these within the stipulated time.

Kindly take the above information on record.

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Mandar Kurghode